Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Stoke Therapeutics Inc (STOK)
NASDAQ:STOK
Holding STOK?
Track your performance easily
STOK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.78 - $17.58
Previous Close$12.11
Volume176.51K
Average Volume (3M)566.05K
Market Cap
$641.43M
Enterprise Value$402.23M
Total Cash (Recent Filing)$239.20M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Mar 05, 2025EPS Estimate
-$0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.10
Shares Outstanding52,966,977
10 Day Avg. Volume556,146
30 Day Avg. Volume566,051
Standard Deviation0.22
R-Squared0.05
Alpha-0.00227
Financial Highlights & Ratios
Price to Book (P/B)2.58
Price to Sales (P/S)36.73
Price to Cash Flow (P/CF)-7.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue24.03
Enterprise Value/Gross Profit45.81
Enterprise Value/Ebitda-3.67
Forecast
1Y Price Target
$23.17Price Target Upside91.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Stoke Therapeutics News
PremiumCompany Announcements
Stoke Therapeutics Gains FDA Breakthrough for Epilepsy Drug
PremiumCompany Announcements
Stoke Therapeutics Reports Q3 Results, Focuses on Phase 3 Study
Bulls Say, Bears Say
Bulls Say
Clinical DataZorevunersen shows durable reductions in convulsive seizure frequency, supporting Stoke's strategy to maximize its potential to reduce seizure frequency while maintaining an encouraging safety profile.
Financial StabilityThe 3Q24 cash balance of $269M is sufficient into the second half of 2026.
Regulatory ProgressEncouraging seizure reduction with zorevunersen (STK-001) in Dravet syndrome suggests potential success in Phase 3 trials.
Bears Say
Clinical TrialsSTOK is delaying the start of the STK-002 Ph1/2 trial in Autosomal Dominant Optic Atrophy pending the outcome of the DS regulatory talks.
Regulatory ApprovalRisks to the investment thesis include failure to secure regulatory approval in the US and EU.
Revenue EstimatesFailure to achieve peak commercial revenue estimates poses a significant risk.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
STOK FAQ
What was Stoke Therapeutics Inc’s price range in the past 12 months?
Stoke Therapeutics Inc lowest stock price was $3.78 and its highest was $17.58 in the past 12 months.
What is Stoke Therapeutics Inc’s market cap?
Currently, no data Available
When is Stoke Therapeutics Inc’s upcoming earnings report date?
Stoke Therapeutics Inc’s upcoming earnings report date is Mar 05, 2025 which is in 73 days.
How were Stoke Therapeutics Inc’s earnings last quarter?
Stoke Therapeutics Inc released its earnings results on Nov 05, 2024. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.52 by $0.05.
Is Stoke Therapeutics Inc overvalued?
According to Wall Street analysts Stoke Therapeutics Inc’s price is currently Undervalued.
Does Stoke Therapeutics Inc pay dividends?
Stoke Therapeutics Inc does not currently pay dividends.
What is Stoke Therapeutics Inc’s EPS estimate?
Stoke Therapeutics Inc’s EPS estimate is -$0.54.
How many shares outstanding does Stoke Therapeutics Inc have?
Stoke Therapeutics Inc has 52,966,976 shares outstanding.
What happened to Stoke Therapeutics Inc’s price movement after its last earnings report?
Stoke Therapeutics Inc reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.52. Following the earnings report the stock price went down -0.382%.
Which hedge fund is a major shareholder of Stoke Therapeutics Inc?
Among the largest hedge funds holding Stoke Therapeutics Inc’s share is Baker Bros Advisors LP. It holds Stoke Therapeutics Inc’s shares valued at 54M.
---
Stoke Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.17 (91.33% Upside)
$23.17 (91.33% Upside)
Blogger Sentiment
Bullish
STOK Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 13.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $27.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
214.54%
12-Months-Change
Fundamentals
Return on Equity
-52.06%
Trailing 12-Months
Asset Growth
22.27%
Trailing 12-Months
Company Description
Stoke Therapeutics Inc
Stoke Therapeutics, Inc. engages in the research and development of treatments for genetic diseases. It is a biotechnology firm that focuses to increase gene expression to treat severe genetic diseases, including genetic conditions affecting the central nervous system, eye, ear, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
---
STOK Stock 12 Month Forecast
Average Price Target
$23.17
▲(91.33% Upside)
Technical Analysis
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering STOK
1 Year
1 Year Success Rate
8/14 ratings generated profit
1 Year Average Return
+38.09%
reiterated a buy rating 2 months ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +38.09% per trade.
---